WO2013129889A2 - 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름 - Google Patents

실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름 Download PDF

Info

Publication number
WO2013129889A2
WO2013129889A2 PCT/KR2013/001679 KR2013001679W WO2013129889A2 WO 2013129889 A2 WO2013129889 A2 WO 2013129889A2 KR 2013001679 W KR2013001679 W KR 2013001679W WO 2013129889 A2 WO2013129889 A2 WO 2013129889A2
Authority
WO
WIPO (PCT)
Prior art keywords
film
sildenafil
fast
oral
active ingredient
Prior art date
Application number
PCT/KR2013/001679
Other languages
English (en)
French (fr)
Korean (ko)
Other versions
WO2013129889A3 (ko
WO2013129889A9 (ko
Inventor
정현준
장익현
김달근
이진후
엄진희
김현수
정경태
연규정
박진규
Original Assignee
주식회사 서울제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120020316A external-priority patent/KR101328350B1/ko
Priority claimed from KR1020120117233A external-priority patent/KR101440808B1/ko
Application filed by 주식회사 서울제약 filed Critical 주식회사 서울제약
Priority to CA2864322A priority Critical patent/CA2864322C/en
Priority to JP2014554675A priority patent/JP5941558B2/ja
Priority to IN1706MUN2014 priority patent/IN2014MN01706A/en
Priority to CN201380010759.1A priority patent/CN104168895B/zh
Priority to US14/379,989 priority patent/US10092651B2/en
Priority to EP13755861.5A priority patent/EP2821066B1/en
Publication of WO2013129889A2 publication Critical patent/WO2013129889A2/ko
Publication of WO2013129889A3 publication Critical patent/WO2013129889A3/ko
Publication of WO2013129889A9 publication Critical patent/WO2013129889A9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Definitions

  • the present invention relates to a rapid-release film containing sildenafil or a pharmaceutically acceptable salt thereof in high content. More specifically, sildenafil or a pharmaceutically acceptable salt thereof, which was not previously considered possible by using a specific plasticizer in a specific content, contains at least 100 mg per film or 50% of the total weight of the film. It relates to a quick-dry film.
  • the present invention relates to a quick-release film containing sildenafil or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the high taste of the active ingredient is concealed. More specifically, the present invention relates to a concealed fast-release film, characterized in that it contains sildenafil or a pharmaceutically acceptable salt thereof as an active ingredient and contains a specific bite-cloaking agent.
  • the present invention is a rapid-release film in the form of an oral film containing sildenafil or a pharmaceutically acceptable salt thereof in a high content, containing a specific bite masking agent or a combination of bite masking agent,
  • the present invention relates to a quick-release film that does not adversely affect film formation.
  • Erectile dysfunction refers to a condition in which normal sexual life is not possible, such as difficulty in inducing or maintaining an erection for sexual intercourse, or ejaculation disorders such as premature ejaculation or seborrhea, and extreme feeling. 3-5% of American men aged 18-75 have chronic erectile dysfunction, the majority of whom are reported to be 55 or older.
  • a drug that can inhibit subtype 5 of cGMP phosphodiesterase can be used.
  • PDEv inhibitors inhibit the degradation of cGMP and increase the concentration of cGMP in the tissue.
  • concentration of cGMP in the tissue is increased, the blood flow to the cavernous tissues of the penis is increased, resulting in relaxation of the penile smooth muscle, thereby treating erectile dysfunction. It becomes possible.
  • PDEv inhibitors known to date include Vardenafil, [3- (1,4-Dihydro-5-methyl-4-oxo-7-propylimidazo [5,1-f] [1,2 , 4] triazin-2-yl) -4-ethoxyphenyl] sulfonyl] -4-ethyl, C23H32N6O4S, CAS no.224785-90-4), sildenafil, 1-[[3- (6, 7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl) -4-ethoxyphenyl] sulfonyl] -4-methylpipe Razine, 22H30N6O4S, CAS no.
  • tadalafil (Tadalafil, pyrazino [1 ', 2': 1,6] pyrido [3,4-b] indole-1,4-dione , 6- (1,3-benzodioxol-5-yl) -2,3,6,7,12,12a-hexahydro-2-methyl-, (6R, 12aR)-, C22H19N3O4, CAS no. 171596 -29-5), udenafil (Udenafil, C25H36N6O4S, CAS no. 268203-93-6) and the like. Vardenafil is disclosed in Korean Patent No. 0430355, Sildenafil in Korean Patent No.
  • PDEv inhibitors are commercially available as oral erectile dysfunction drugs in the form of tablets prepared using water soluble salts to ensure rapid absorption and good bioavailability in formulation.
  • sildenafil is a drug used for the treatment of erectile dysfunction, angina and pulmonary hypertension.
  • Sildenafil was originally used as a treatment for angina. It was developed as a therapeutic agent for erectile dysfunction, and sildenafil citrate salt was approved by the US FDA in March 1998 and has been used as the most widely used medicine in the treatment of erectile dysfunction. In Korea, it is marketed since October 1999 under the trade name Viagra® tablet.
  • sildenafil is a drug to be administered immediately before sexual activity, it is often administered at irregular intervals, and in some cases, it is urgently administered in a situation that is not scheduled in advance, and thus it is easy to carry it.
  • attempts have been made to develop formulations which can be easily taken without water, rather than as conventional tablets or capsules.
  • Korean Patent Laid-Open Publication No. 2006-31552 discloses an oral quick-release composition for PDE-5 inhibitors containing PDEv inhibitors such as sildenafil as an active ingredient, wherein sildenafil is enclosed with cyclodextrin.
  • PDEv inhibitors such as sildenafil as an active ingredient
  • ODT tablet formulation
  • Korean Patent No. 627199 discloses a soluble film type formulation (ODF) which uses sildenafil citrate as an active ingredient and rapidly dissolves in the oral cavity, wherein a hydrocolloid is used as a film forming polymer, and a film formulation
  • ODF soluble film type formulation
  • a starch graft copolymer as a mucoadhesive enhancer
  • the fast-drying film containing sildenafil is easily disintegrated or dissolved in the oral cavity and can be taken without water, so not only the elderly who have difficulty in taking tablets or capsules, but also children with disabilities, patients lying in bed, and busy It is also very useful for modern people. While it is possible to prescribe liquid formulations in place of tablets or capsules for the elderly and children, liquid formulations have the disadvantages of poor stability and inaccurate dosage.
  • the fast-release film is a useful new formulation that can be applied to drugs that are highly metabolized among the drugs absorbed from the digestive tract.
  • Film preparations are usually film-type preparations that disintegrate within 1 minute, so the thickness is 50-150 ⁇ m and the size is 22 mm by 32 mm in width and 7 cm 2 in width. Some formulations have slightly increased the width and width, but more than 10 cm2 have not been reported in consideration of consumer convenience. Due to the limitation of thickness and size, a product of about 50mg to 150mg per commercial film is commercialized.
  • Novartis' Gas-X Thin Strips® is a commercially available high-content product that has a weight of 110mg per film and 62.5mg of active ingredient (Simethicone). It is known to be the only fast-acting film formulation contained and commercialized. In general, the content of a suitable active ingredient per film is known to be less than about 30%. If more than 30% of the active ingredient is contained, the physical properties of the film are weakened, leading to increased brittleness and cracking during manufacturing and distribution. It is difficult. Gas-X thin strip is the only commercially available fast-release film formulation with brittleness of 50% or more active ingredient.
  • Sildenafil citrate-containing formulations are currently marketed by Pfizer under the Viagra® brand and are available in three doses of 25 mg, 50 mg and 100 mg. In the case of 100 mg, it is 100 mg as sildenafil, so it is 140.45 mg in actual sildenafil citrate, which is larger than the weight of the commercially available high-content gas-X. Therefore, in order to make 100 mg of sildenafil into a film, a formulation containing more than 50% of the active ingredient should be designed.
  • the weight of the film is about 281 mg
  • the thickness of the film is not only too thick at 280 ⁇ m, but also the physical properties and brittleness of the film are significantly weakened, making it difficult to prepare.
  • sildenafil citrate is so bitter that additional coding, ion exchange resin adsorption, or masking aids must be used, in which case the thickness becomes thicker and the film properties and brittleness become worse.
  • US Patent Publication No. 2008/0220029 discloses a rapid-release film containing at least 40% of the active ingredient of the film weight.
  • This patent discloses a fast-release film such as ibuprofen masked through a pre-coating process as an example.
  • US 2008/0233174 discloses a rapid-release film containing at least 30% of the active ingredient in the film weight. Examples of this patent disclose the use of encapsulated acetaminophen. It is a patent for manufacturing high-content fast-use film after pre-masking through coating or encapsulation and describes high-quality fast-use film through the use of two kinds of polymers having different glass transition temperatures.
  • US Patent US652024 discloses a quick release film containing sildenafil citrate. However, even though sildenafil citrate is used as an active ingredient, no technique for masking is shown. The fast-acting film preparations have industrial applicability only when the active ingredients disintegrate or dissolve in the oral cavity, masking the bitter or unpleasant taste of the active ingredients.
  • US Patent Publication 2009/0047330 which describes the masking of sildenafil formulations, discloses an oral rapid film composition of a PDE-5 inhibitor containing PDEv inhibitors such as sildenafil as an active ingredient, wherein the masking of sildenafil with cyclodextrin is disclosed. The embodiment which carried out is disclosed.
  • Korean Patent No. 1074271 stevioside-based sweeteners and high sweeteners have been used to improve aftertaste, but this is an attempt to suppress the bitter taste of the active ingredient using a combination of conventional sweeteners.
  • the content of the active ingredient is 0.1 to 30% by weight (w / w) relative to the film weight, the embodiment of more than 40% by weight (w / w) relative to the total weight of the formulation
  • Invisible U.S. Patent Application Publication No. 2007/0292515 discloses loading ketoprofen having an increased pH into a film formulation using an alkalizing agent such as sodium hydroxide as a means of concealing the delicacy of ketoprofen.
  • Korean Patent No. 10-1188594 discloses masking of bitter taste by sodium hydroxide, sodium hydrogen carbonate or a mixture thereof.
  • Korean Patent Publication No. 10-2012-0101301 discloses a technique using sildenafil free base. This also describes examples in which the content of the active ingredient is 50% or less.
  • the fast dissolving film with a high content of at least 50% concealing the delicacy of the active ingredient It is believed that there is no formulation which significantly improves the brittleness of the. In the case of concealing bitter gourd, film properties and brittleness are remarkably inferior, and in the case of good film properties, it is difficult to manufacture a commercially available Viagra 100mg-containing film formulation containing commercially available low-content active ingredients.
  • the present invention to solve the problem to provide a soyongyong film containing sildenafil citrate or a pharmaceutically acceptable salt thereof in a high content.
  • the reason why the high content of the active ingredient is not loaded into the film formulation is that the brittleless problem of the film is seriously raised when the active ingredient is included in 50% or more of the total weight of the film.
  • the present invention even if the effective ingredient is loaded with high content and the problem of brittleness is solved, the medication compliance of the patient is remarkably inferior when administration of sildenafil citrate as an effective ingredient is not effectively concealed. In view of this, it is a further problem to provide a high hiding means specialized for the present formulation.
  • an object of the present invention to provide a quick-release film characterized in that the delicacy of sildenafil is concealed by using a combination of a specific anti-cloaking agent and / or a specific high-cloaking agent.
  • the present invention is a fast disintegrating film in the oral cavity containing sildenafil or a pharmaceutically acceptable salt thereof as an active ingredient, by using a combination of specific high hiding agents to conceal the taste of the active ingredient and
  • an object of the present invention is to provide a pharmaceutical composition characterized by having excellent film forming ability.
  • the last technical feature of the present invention is a rapid-release film containing sildenafil citrate or a pharmaceutically acceptable salt thereof in a high content, wherein the combination of a specific bitumen and / or a specific bitumen It relates to a fast-use film, characterized in that by using the tare completely concealed.
  • a technical significance of the present invention to provide a fast-release film that achieves a high hiding effect, and at the same time does not cause a problem in the film forming ability while mounting such a high content.
  • the plasticizer is glycerin fatty acid ester, sucrose fatty acid ester, lecithin, enzyme-treated lecithin, polysorbate, sorbitan fatty acid ester, sorbitol, maltitol, xylitol, glycerin, polyethylene glycol, propylene glycol, hydrogenated
  • a quick-release film characterized in that selected from the group consisting of starch syrup, starch syrup, glycerin, triacetin, glycerol oleate, sucrose fatty acid ester, and medium chain fatty acid.
  • the flux film is characterized in that the plasticizer comprises glycerin or sorbitol.
  • the water-soluble hydrocolloid is pullulan, gelatin, pectin, low viscosity pectin, hydroxypropyl methyl cellulose, low viscosity hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose , Polyvinyl alcohol, polyacrylic acid, methyl methacrylate copolymer, carboxyvinyl polymer, polyethylene glycol, alginic acid, low viscosity alginic acid, sodium alginate, carrageenan, modified starch, casein, whey protein isolate, soy protein isolate, zein, Disclosed is a quick-release film characterized in that it is selected from the group consisting of levane, elcinan, gluten, acacia gum, carrageenan, arabian gum, guar gum, locust bean gum, xanthan gum, gellan gum and agar.
  • the hydrocolloid is selected from the group consisting of pullulan, xanthan gum, locust bean gum, polyvinyl alcohol, pectin, low viscosity pectin, low viscosity alginic acid and hydroxypropylmethylcellulose.
  • a quick-release film is disclosed.
  • a quick-release film comprising a high hiding agent selected from the group consisting of sodium, calcium chloride and potassium chloride.
  • the flux mask is disclosed, characterized in that the high hiding agent is sodium hydroxide and / or magnesium oxide.
  • the high-masking agent is magnesium oxide and sodium hydroxide
  • magnesium oxide and sodium hydroxide is a rapid-release film, characterized in that it is contained in a ratio of 1: 4 to 4: 1.
  • the method for producing a fast-acting film (a) a homogeneous stirring of the sildenafil citrate, a film forming agent, a plasticizer, a high hiding agent and a pharmaceutically acceptable additive to provide a crude liquid for oral film preparation preparation Making;
  • step (C) a method for producing an oral film formulation comprising sildenafil citrate comprising the step of slitting and cutting the molded film and filling it into a container or an aluminum wrapping paper, wherein the high hiding in step (a)
  • the agent is selected from the group consisting of magnesium oxide and sodium hydroxide
  • the film formulation is a method for producing a quick-release film, characterized in that the film containing a sildenafil citrate 100mg or more, or 50% or more per gross weight of the film. do.
  • the plasticizer is disclosed a method for producing a fast-use film, characterized in that it comprises glycerin or sorbitol.
  • the sweetener is a method for producing a fast-acting film, characterized in that at least one sweetener selected from aspartame, taumartin or taumartin mixture, sucralose.
  • a method for producing a fast-acting film characterized in that a high sweetness sweetener aspartame, sucralose, taumartin dextrin mixture is used in a ratio of 1: 1.5: 2.
  • step (C) a method for producing an oral film formulation comprising a sildenafil base comprising the step of slitting and cutting the molded film to fill in a container or aluminum wrapping paper, wherein the plasticizer in step (a) is glycerin
  • the present invention discloses a method for producing a fast-acting film, comprising sorbitol and / or polyethylene glycol, and containing at least 100 mg of sildenafil or at least 50% per film total weight.
  • the sweetener is a method for producing a fast-acting film, characterized in that at least one sweetener selected from aspartame, taumartin or taumartin mixture, sucralose.
  • a method for producing a fast-use film characterized in that a high sweetness sweetener aspartame, sucralose, taumartin dextrin mixture is used in a ratio of 1: 1.5: 2.
  • the rapid-release film of the present invention may contain at least 50% of the total weight of the film, or at least 100 mg per film of the total weight of sildenafil or a pharmaceutically acceptable salt thereof as an active ingredient, and at the same time, the amount of the active ingredient, which is a limitation of the film, is increased. Solve the problem of Britleys that occur when, and furthermore has the effect of solving the bitter taste of the active ingredient.
  • bittersweet As a means of concealing bittersweet, the most common one is the use of various kinds of sweeteners, which are often incapable of concealing the bitter enough to make the patient unable to feel bitter taste. Many means have been devised to control the particle size of an active ingredient, to use a clathrate compound, to coat a drug with an insoluble polymer, or to use a solid dispersion.
  • PDEv inhibitors such as sildenafil citrate
  • ODT or ODF are drugs with extremely strong bitterness
  • attempts have been made to develop them into ODT or ODF, which are rapidly disintegrating formulations in the oral cavity.
  • ODT or ODF are rapidly disintegrating formulations in the oral cavity.
  • it is believed that it is difficult to effectively achieve the high concealment effect at the same time without compromising the original properties of the ODT or ODF formulation.
  • the pharmaceutical composition of the present invention can be, for example, oral film formulations, such oral film formulations eliminate the difficulty and fear of taking in patients suffering from swallowing, such as the elderly and the disabled It is possible to improve the safety and effectiveness by administering the correct dose when compared to the liquid solution, and depending on the drug, it is designed to directly deliver the drug without the first pass effect through the oral mucosa. It is possible to improve bioavailability, resulting in faster efficacy at relatively lower doses.
  • the oral film formulation is an individual package (Unit package) different from the existing formulations (Unit package), there is an advantage that it is easy to carry and store.
  • PDEv inhibitors such as sildenafil or pharmaceutically acceptable salts thereof, as oral film formulations.
  • the first is a problem regarding the film-forming ability and the payload of the active ingredient.
  • sildenafil citrate when used as an active ingredient, 50 mg and 100 mg are present in Viagra tablets that are currently commercially available. Although it is necessary to mount, it is considered technically very difficult to mount 100 mg or more of the active ingredient in the film formulation. Because the amount of the active ingredient increases, the amount of the film-forming agent should be increased, but due to the nature of the film formulation that needs to disintegrate quickly in the oral cavity, strict restrictions are imposed on the formulation size, thickness, and gross weight of the limited film formulation.
  • the fast-use film containing sildenafil citrate in a high content it is difficult to derive a means for concealing the gourd without affecting the film forming ability.
  • the present inventors have intensively studied various high-hiding concealment means that have been used in the past when the high-drug drug is included in oral films.
  • the present inventors apply the conventional means to a rapid-release film having a high content of an active ingredient as in the present invention. In this case, it has been found that no high concealment effect is exhibited at all, or that the film is not formed due to the conventional high concealment concealment means, or that the quality of the film is extremely poor and is not suitable as a commercially available product.
  • the conventional prescription when containing the sildenafil citrate as 100mg or more as in the present invention, it was found that the application of a known high-level concealment means has a fatal adverse effect on the film-forming ability.
  • the amount of the components other than the active ingredient, for example, the film forming agent becomes very small compared to the conventional prescription. Under such circumstances, it means that the conventionally known high hiding means cannot be applied as it is.
  • the above three problems are not problems that occur independently of each other, but are organically related to each other, so it is very difficult to solve them. That is, in order to reinforce the high concealment means, when a large amount of sweetener or a cyclodextrin is used, it is impossible to mount the active ingredient in a high content in the inner film, and there is a problem in the film forming ability or brittleness Can not improve the problem. In addition, when the amount of the film-forming agent is increased in order to solve the problem of Brittle, there is a limit in increasing the amount of the active ingredient. In other words, in order to maximize the amount of the active ingredient, conceal the gourmet and solve the problem of Britness, a new and advanced prescription that does not exist previously is required.
  • the present inventors have repeatedly conducted studies, including technical means that can solve the above three problems at the same time, that is, containing a high content of the active ingredient, while maintaining excellent film-forming ability and effectively concealing the delicacy of the effective ingredient It is also possible to derive new technical means to solve the problem of Britness and to reach the present invention. That is, the present inventors, after intensive research, used sodium hydroxide as a high-closure means while using a specific plasticizer in a specific content in a fast-release film containing sildenafil or a pharmaceutically acceptable salt thereof in a high content. In the case of using a combination of magnesium peroxide, the present inventors have been found to solve the problem of brittleness and effectively conceal the bitterness.
  • the oral film formulation of the present invention may contain a therapeutically effective amount of an active ingredient, an alkalizing agent, a high sweetener, a film forming agent, and a pharmaceutically acceptable additive, and when taken without water Completely disintegrating and / or dissolving within the oral cavity within 100 seconds, preferably within 60 seconds, more preferably within 30 seconds, will migrate to the gastrointestinal tract for absorption.
  • preferred oral film formulations according to the present invention contain sildenafil or a pharmaceutically acceptable salt thereof in high amounts, i.e., at least 50% of the total weight of the film or at least 100 mg per film.
  • Sweeteners, film formers, and additional ingredients which may include pharmaceutically acceptable thickeners, fillers, additional sweeteners, acidulants, flavoring agents, surfactants, water-soluble polymers, preservatives, colorants, coolants, and the like. Possible additives may be.
  • the components are described in detail as follows.
  • bittersweet As a means of concealing bittersweet, the most common one is the use of various kinds of sweeteners, which are often incapable of concealing the bitter enough to make the patient unable to feel bitter taste. Many means have been devised to control the particle size of an active ingredient, to use a clathrate compound, to coat a drug with an insoluble polymer, or to use a solid dispersion.
  • PDEv inhibitors such as sildenafil citrate
  • ODT or ODF are drugs with extremely strong bitterness
  • attempts have been made to develop them into ODT or ODF, which are rapidly disintegrating formulations in the oral cavity.
  • ODT or ODF are rapidly disintegrating formulations in the oral cavity.
  • it is believed that it is difficult to effectively achieve the high concealment effect at the same time without compromising the original properties of the ODT or ODF formulation.
  • the effective content is contained in a high content, when applying a conventional high-level concealment means, the high-detail concealment effect is not excellent, or the problem of Britney or the film itself There is a problem that is not formed.
  • the present invention discloses the following new high-level concealment means.
  • the high hiding agent is used to conceal the bitterness of sildenafil citrate by adjusting the pH of the crude liquid for forming the oral film in the range of 4.8 to 7. That is, according to the research of the present inventors, the bitterness of the oral film preparation containing sildenafil citrate obtained the knowledge that the effective bite masking was not effective only by using a general sweetening agent. And / or by using a combination of specific gummy masking agents, knowledge was obtained by adjusting the pH range of the crude liquid to the above range.
  • the amount of the gas masking agent can be adjusted as appropriate within the range that can be adjusted to the pH range, but preferably it is preferably included in 1.0 to 10.0% by weight Let's make knowledge.
  • Another great feature of the present invention is that, due to the combination of a specific high concealment agent and / or a specific high concealment agent in the above high concealment agent, it does not adversely affect film formation, and in particular, the problem of brittleness
  • the best range that does not occur is derived. That is, according to the study of the present inventors, when using a combination of the sweetening agent to adjust the pH range and using a combination of sweeteners, etc., it was possible to achieve the high-cloaking effect, the film is not well formed, further brittleness We found an unexpected problem that a problem occurred. In other words, when the content of sildenafil citrate is high, it is difficult to form a fast-acting film formulation that can be actually produced by simply adjusting the pH to the above range.
  • magnesium oxide and sodium hydroxide are preferably used in a ratio of 1: 4 to 4: 1, and the amount of magnesium oxide and sodium hydroxide is preferably 1 to 10% of the total formulation weight.
  • the pharmaceutical composition of the present invention may include a sweetener.
  • sweeteners sugar, glucose, maltose, oligosaccharide, galactose, syrup, sorbitol, maltitol, invert sugar, xylitol, erythritol, hydrogenated syrup, mannitol, trehalose, aspartame, acesulfame salt, sucralose, saccharin salt, neotime, tao
  • It may be one or more high sweetening sweeteners selected from the group consisting of martin, tomatin mixtures, cyclate salts, taumartin, Nahan fruit extract, licorice extract, stevioside, enzyme treatment stevioside, neohesperidine and monelin. More preferably, it may be one or more high sweetening sweeteners selected from aspartame, tomatin mixture, sucralose, neotime, acesulfame.
  • the oral film formulation of the present invention contains a water-soluble polymer as a film forming agent.
  • Water-soluble polymers include pullulan, gelatin, pectin, low viscosity pectin, hydroxypropylmethyl cellulose, low viscosity hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, polyacrylic acid, methyl Methacrylate copolymer, carboxyvinyl polymer, polyethylene glycol, alginic acid, low viscosity alginic acid, sodium alginate, carrageenan, modified starch, casein, whey protein isolate, soy protein isolate, zein, levan, elcinane, gluten, acacia gum It may be at least one water-soluble polymer selected from the group consisting of, carrageenan, gum arabic, guar gum, locust bean gum, xanthan gum, gellan gum and agar.
  • it may be at least one water-soluble polymer selected from the group consisting of pullulan, gelatin, pectin, low viscosity pectin, low viscosity alginic acid, hydroxypropylmethylcellulose and modified starch.
  • the water-soluble polymer may contain 5 to 70% by weight (w / w) based on the total weight of the oral film formulation.
  • the pharmaceutically active ingredient used in the oral film formulation of the present invention may be a pharmacologically active ingredient administered orally.
  • Antidiabetic agents such as, for example, glimepiride, pioglitazone, and the like; Agents for treating insomnia such as zolpidem, eszopiclone and the like; Urogenital therapeutics such as tolterodine, tropium and the like; Anti-obesity agents such as sibutramine and the like; Enzymes such as streptokinase and the like; Peptic ulcer solvents such as omeprazole; Antitussive expectorants such as theophylline, glenbuterol and the like; Skin disease treatment agents such as finasteride and the like; Antiemetic agents such as ondansetron; Antidepressants such as fluoxetine and the like; Antihistamines such as fexofenadine hydrochloride; Antipyretic analgesic agents such as aspirin, ibuprofen, ketoprofen, meloxycam and the like; Hormonal agents such as testosterone and the like; Therapeutic agents for circulatory organ
  • triclosan cetyl pyridium chloride, domiphen bromide, quaternary ammonium salt, zinc compound, acid guinarin, fluoride, alexidine, octonidine, EDTA, aspirin, acetaminophen, ibuprofen, ketoprofen, diflunisal, Phenopropenecalcium, naproxen, sodium tolmectin, indomethacin, benzonatate, caramiphene, edylate, menthol, dextromethropan hydrobromide, crofedianol hydrochloride, diphenhydramine, pseudoephedrine, phenyle Ferrin, phenylpropanolamine, pseudoephedrine sulfate, brompheniramine maleate, chlorpheniramine maleate, carbinoxamine maleate, clemastine fumarate, dexchlorpheniramine maleate, diphenhydramine hydrochloride
  • Oral film formulations of the present invention may comprise a filler.
  • the filler serves to maintain the density and shape of the film. It also reduces the sticking properties of the films, and can control the sticking and dissolution rate of the film in the oral cavity and the dissolution rate of the drug.
  • the filler may be added 0.5 to 10% by weight (w / w) relative to the total weight of the oral film formulation.
  • the filler is at least one selected from the group consisting of microcrystalline cellulose, cellulose polymers, microcrystalline cellulose carboxymethylcellulose sodium, magnesium carbonate, calcium carbonate, limestone powder, silicate, clay, talc, titanium dioxide and calcium phosphate It may be a component.
  • Oral film formulations of the present invention may comprise a plasticizer.
  • the plasticizer can be used to adjust the flexibility and brittleness of the film.
  • a feature of the present invention is that the amount of sildenafil citrate contained in the film is at least 50% or at least 100 mg of the total weight of the film.
  • sildenafil citrate is used in a high content as described above, according to a conventional prescription, brittleness problem occurs and does not become an actual commercially available product.
  • sildenafil citrate is available in three dosages of 25 mg, 50 mg, and 100 mg under the trade name Viagra, and the 100 mg dose is about 140.45 mg of sildenafil citrate.
  • the film preparation when 50% of the total weight of the film is used as an active ingredient, 280 mg of the fast-acting film preparation should be made.
  • the formulation of 250 mg or more is large enough to make it difficult to administer the film to the oral cavity at once.
  • the thickness is 27 mm and 32 mm, which makes the film thicker and less commercially available.
  • 27mm length 32mm weight was about 220mg, while limiting the film formulation, it was intended to produce a quick-release film that can contain the amount of sildenafil 100mg.
  • the content of sildenafil citrate per sheet of the fluxing film is 60-70%, which is a high-content fluxing film, and when such a film is manufactured by applying a conventional prescription, the flexibility and strength of the film are significantly reduced.
  • the brittleness is remarkably deteriorated, and when opened from an aluminum silver foil wrapper and subjected to a bending test after opening under conditions of a relative humidity of 55% RH and a temperature of 22 ° C, it is found that most of them break immediately.
  • the present inventors have diligently studied to improve the brittleness of such high content formulations. As a result, the brittleness is significantly improved when administered by 1% to 10% glycerin, 0.1 to 10% sorbitol, or a combination thereof. New knowledge has been obtained that a fast film can be produced. That is, when using the plasticizer as described above, the amount of the film-forming agent is at least, the problem of brittleness does not occur, and furthermore, even with the high hiding means by the combination of sodium hydroxide and magnesium oxide first proposed in the present invention In connection, I learned that the rice was completely removed.
  • the plasticizer is glycerin fatty acid ester, sucrose fatty acid ester, lecithin, enzyme treatment lecithin, polysorbate, sorbitan fatty acid ester, sorbitol, maltitol, xylitol, glycerin, polyethylene glycol, propylene glycol, hydrogenated syrup, starch syrup, glycerin, It may be one or more components selected from the group consisting of triacetin, glycerol oleate, sucrose fatty acid esters and medium chain fatty acids, most preferred is glycerin or sorbitol as described above.
  • Oral film formulations of the present invention may also further comprise an acidulant.
  • the acidulant together with the sweetener, controls the taste and may play a role in stimulating the generation of saliva so that the edible film can be dissolved well.
  • the acidulant may be added 0.5 to 10% by weight (w / w) relative to the total weight of the oral film formulation composition.
  • the acidulant may be at least one component selected from the group consisting of citric acid, malic acid, fumaric acid, tartaric acid, ascorbic acid, succinic acid, adipic acid and lactic acid.
  • Oral film formulations of the present invention may also comprise perfumes.
  • the oral film formulation of the present invention is a product that is dissolved and absorbed in the oral cavity, it is necessary to add an appropriate flavor.
  • the flavor may be natural flavors, artificial flavors or mixtures thereof.
  • Natural flavors may be extracts from the leaves, flowers, fruits and the like of plants, oils of plants and the like.
  • Plant oils include spearmint oil, cinnamon oil, peppermint oil, lemon oil, clove oil, bay oil, thyme oil, cedar leaf oil, nutmeg oil and sage ( sage) oil, almond oil, and the like.
  • artificial flavors of fruits such as lemons, oranges, grapes, limes, strawberries and artificial synthetic flavors such as vanilla, chocolate, coffee, cocoa, pine needles, ginseng, red ginseng, citrus may be used.
  • the amount of fragrance used depends on a number of factors such as the type, type, and desired strength of the fragrances commonly used, and may generally comprise 0.1 to 10.0 wt% (w / w) relative to the total weight of the oral film formulation.
  • Perfume in oil form may be used together with an emulsifier to make it compatible with water-soluble substances.
  • the amount of the emulsifier may be adjusted according to the type and amount of the fragrance, and generally 0.5 to 10% by weight (w / w) relative to the total weight of the oral film formulation.
  • the oral film formulation of the present invention may contain a pigment suitable for the product.
  • the pigment may be appropriately adjusted in its content as necessary, and in general, 0.1 to 1.0% by weight (w / w) may be added to the total weight of the oral film formulation.
  • the pigment may be a natural or synthetic pigment.
  • Oral film formulations of the present invention may also further comprise a cooling agent.
  • the refreshing agent may be, but is not limited to, for example, l-menthol, WS3, WS23, or Questais-L.
  • the refreshing agent can be appropriately adjusted in accordance with the content, if necessary, and generally can be added to 10% by weight (w / w) or less relative to the total weight of the oral film formulation.
  • Oral film formulations of the present invention may further include a bad breath remover to reduce oral odors.
  • the bad breath remover may be a metal salt.
  • the metal salt may be, for example, one or more components selected from the group consisting of metal salts of chlorite, copper gluconate, zinc chloride, zinc citrate and zinc gluconate.
  • the bad breath remover is triclosan, alexidine, hextidine, benzalkonium chloride, salicylicanilide, domiphen bromide, tetradecylpyridinium chromide, N-tetradecyl-4-ethylpyridinium chloride , Octenidine, iodine, sulfonamide, bisbiguanide, phenols, delmopinol, octapinol, chlorhexitin, nisin preparation, nystatin, sangguinrin, cetylpyridinium chloride, red ginseng extract, green tea With extract, seaweed extract, herbal extract, grapefruit extract, apple extract, thyme, thy
  • the thickness of the oral film formulation of the present invention is 50 ⁇ m to 300 ⁇ m, preferably 60 ⁇ m to 280 ⁇ m, most preferably 70 ⁇ m to 260 ⁇ m.
  • the size of the oral film formulation of the present invention is 1 cm 2 to 12 cm 2, preferably 2 cm 2 to 10 cm 2, and more preferably 4 cm 2 to 8 cm 2.
  • the present invention also provides a method for preparing the oral film formulation.
  • the method for preparing the oral film formulation of the present invention provides a method for preparing the oral film formulation. In one embodiment, the method for preparing the oral film formulation of the present invention
  • the oral film forming composition was introduced into a molding machine to mold the film at 15 to 150 ° C, preferably 25 to 120 ° C, more preferably 40 to 100 ° C;
  • (3) may comprise aging the molded film for 1 to 30 days at 30 to 90% relative humidity.
  • the method for preparing the oral film formulation according to the present invention may be carried out through the following process, for example.
  • a sweetening agent a flavoring agent, a water-soluble polymer, and a coloring agent are added thereto, followed by homogeneous stirring to prepare a crude liquid for oral film preparation.
  • the final pH of the crude liquid ranges from 4.8 to 7, and preferably magnesium oxide and / or sodium hydroxide can be used as a high hiding agent, and glycerin and / or sorbitol can be used as a plasticizer.
  • solvent propylene glycol, polygil 35 castor oil, polyethylene glycol 400, polyethylene glycol 300, trichlormonofluoromethane, sodium hydrogencarbonate, ethyl acetate, water for injection, refined soybean oil, purified water, isopropanol, Liquid paraffin, sodium chloride, ethanol, acetone, physiological saline solution, benzyl alcohol, isopropyl myristin, anhydrous ethanol, sterile purified water, N-methylpyrrolidone, glycerin, methylene chloride, toluene
  • at least one solvent selected from the group consisting of sterile purified water, water for injection, purified water, isopropanol, ethanol, methylene chloride, toluene more preferably selected from the group consisting of sterile purified water, purified water, ethanol, methylene chloride, toluene
  • One or more solvents may be selected from the group consisting of sterile pur
  • the coating solution is introduced into a molding machine to mold a film.
  • the temperature of the molding machine is 15 to 150 °C, preferably 25 to 120 °C, more preferably 40 to 100 °C to form a film, it is produced in a roll form.
  • the molded film contains water suitable for slitting or cutting through a aging process of about 1 to 30 days at a relative humidity of 30 to 90%. At this time, the water content is suitably 15% or less.
  • Aged rolls are slit into small rolls, cut into appropriate sizes, and filled into small containers or aluminum wrappers.
  • Packaging process Filled small containers or aluminum packaging products are repacked in small boxes or made into blisters.
  • the present invention contains sildenafil or a pharmaceutically acceptable salt thereof as an active ingredient, and 1.0 to 12.0% by weight of magnesium oxide (MgO) and / or sodium hydroxide (NaOH), which are high hiding agents, respectively, w / w), the pH of the crude liquid is maintained at 4.8-7, and aspartame and Tallin MD90 are contained in the range of 1.0% to 4.0%, respectively, as a sweetening agent to effectively form the film and effectively mask the unpleasant taste of the drug.
  • MgO magnesium oxide
  • NaOH sodium hydroxide
  • An embodiment of the present invention is a group of examples relating to high hiding and film forming ability (hereinafter referred to as Example A group) and a group of examples relating to high hiding and film forming ability and high content loading (hereinafter referred to as Example B group). Explained by dividing.
  • compositions for oral film preparations were prepared as described in Tables 1 and 2 below, and the pH, gloss score, and film forming ability of the crude liquid were evaluated according to the following criteria.
  • -Drying stage overdrying, poor drying, phase separation, edge warping (curling), foaming, spotting, etc.
  • compositions for oral film preparation were prepared as described in Tables 3 and 4 below, and the pH, glutamate score and film forming ability of the crude solution were evaluated.
  • a pharmaceutical composition for oral film preparation was prepared as described in Table 5 below, and the pH, gloss score, and film forming ability of the crude liquid were evaluated.
  • a pharmaceutical composition for oral film preparation was prepared as described in Table 6 below, and the pH, glutamate score and film forming ability of the crude liquid were evaluated.
  • each component included in one film is represented by weight%.
  • the bending test is the number of times when the inner film is folded in half using two fingers.
  • the bending test in Tables 7-9 is performed 30 minutes after opening the inner film wrapped with aluminum film. At this time, the temperature and humidity were 22 °C, 55% RH. The higher the number, the better the brittleness can be estimated.
  • Example 8-Example 15 further tested casting, slitting and cutting suitability as peel test, slitting test and cutting test results with a pilot test run of 20,000 sheets per badge.
  • Example 2 Example 3 Sildenafil Citrate 64.9% (100 mg as sildenafil) 63.8% (100 mg as sildenafil) 63.8% (100 mg as sildenafil) 63.8% (100 mg as sildenafil) Simethicone 55.8% Methocel E15 10.3% Polyoxamer L-44 5.2% Pullulan 17.0% 17.0% 17.0% Polypro 2.1% Propylene glycol 8.2% 8.2% glycerin Polyethylene Glycol 600 8.2% Xylitol 7.2% 8.2% Sorbitol Sodium hydroxide 2.0% 2.0% 2.0% Magnesium oxide 0.7% 0.7% 0.7% Aspartame 1.0% 1.4% 1.4% 1.4% Sucralose 1.0% 1.0% 1.0% 1.0% Tallinn MD90 1.9% 1.9% 1.9% Citric acid 1.0% 1.0% 1.0% 1.0% Peppermint Oil 1.0% Strawberry flavor 1.0% 1.0% 1.0% menthol 0.5% 0.5% 0.5% Polysorbate 20 1.5% 1.5% 1.5% FD &
  • Example 4 Example 5
  • Example 6 Sildenafil Citrate 63.8% 69.8% 67.2% 63.2% Simethicone Methocel E15 Polyoxamer L-44 Pullulan 17.0% 17.0% 17.0% 17.0% Polyvinyl alcohol Polypro Propylene glycol glycerin Polyethylene Glycol 600 0.5% 0.5% 0.5% Xylitol Sorbitol 8.2% Sodium hydroxide 2.0% 4.0% 8.0% 12.0% Magnesium oxide 0.7% 1.4% 0.0% 0.0% Aspartame 1.4% 1.4% 1.4% 1.4% Sucralose 1.0% 1.0% 1.0% 1.0% Tallinn MD90 1.9% 1.9% 1.9% 1.9% Citric acid 1.0% Peppermint Oil Strawberry flavor 1.0% 1.0% 1.0% 1.0% menthol 0.5% 0.5% 0.5% 0.5% Polysorbate 20 1.5% 1.5% 1.5% FD & C Red 40 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% Benzoic acid Sodium EDTA sub Total 100.0% 100.0% 100.0% 100.0% pH
  • Example 10 Example 11
  • Example 12 Sildenafil Citrate 68.3% 67.9 67.3% 65.3% 63.3% Simethicone Metocell E15 Polyoxamer L-44 Pullulan 17.0% 17.0% 17.0% 17.0% Polyvinyl alcohol Polypro Propylene glycol glycerin 1.0% 1.4% 2.0% 4.0% 6.0% Polyethylene Glycol 600 0.5% 0.5% 0.5% 0.5% 0.5% Xylitol Sorbitol 0.5% 0.5% 0.5% 0.5% 0.5% Sodium hydroxide 4.0% 4.0% 4.0% 4.0% 4.0% 4.0% Magnesium oxide 1.4% 1.4% 1.4% 1.4% Aspartame 1.4% 1.4% 1.4% 1.4% 1.4% Sucralose 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% Tallinn MD90 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% Peppermint Oil Strawberry flavor 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% menthol 0.5% 0.5% 0.5% 0.5% Polysorbate 20 1.5% 1.5% 1.
  • Example 16 Sildenafil Citrate 61.3% 59.3% 54.3% 50% (using sildenafil base) Simethicone Metocell E15 Polyoxamer L-44 Pullulan 17.0% 17.0% 17.0% 34% Polyvinyl alcohol Polypro Propylene glycol glycerin 8.0% 10.0% 15.0% 4% Polyethylene Glycol 600 0.5% 0.5% 0.5% 3% Xylitol Sorbitol 0.5% 0.5% 0.5% 3.59% Sodium hydroxide 4.0% 4.0% 4.0% 0% 0% Magnesium oxide 1.4% 1.4% 0% Aspartame 1.4% 1.4% 1.4% 1.4% Sucralose 1.0% 1.0% 1.0% One% Tallinn MD90 1.9% 1.9% 1.9% 0% Peppermint Oil Strawberry flavor 1.0% 1.0% 1.0% One% menthol 0.5% 0.5% 0.5% Polysorbate 20 1.5% 1.5% 1.5% FD & C Red 40 0.01% 0.01% 0.01% 0.01% 0.01% sub Total 100.0% 100.0% 100.0% 100.0% 100.
  • sildenafil base was used to perform crude liquid, molding, slitting, cutting, and packaging according to the formulation described in Table 9, and the manufacturing method described above, followed by sensory test, bending test, and peel test. The test result was as good as the result of Example 10.
  • the bending test is the number of times when the inner film is folded in half using two fingers.
  • the bending test in Tables 6-9 is conducted 30 minutes after opening the inner film wrapped with aluminum film. At this time, the temperature and humidity were 22 °C, 55% RH. The higher the number, the better the brittleness can be estimated.
  • Comparative Example 2 is a fast-acting film to which 72 mg (50 mg of sildenafil citrate) is added as a fast-acting film to which 150 mg of the weight per sheet is added as an example of Korean Patent Registration 10-1188594.
  • Comparative Example 4 is the same formulation except for some excipients, and the prescription and experimental results of yongyong film with 144 mg (100 mg of sildenafil citrate) added sildenafil citrate showed a bitter taste of 200 mm by 25 mm by 32 mm by weight. The film had poor physical properties and poor film formation.
  • Comparative Example 6 measured the effect of additional administration of 1.4% glycerin to the formulation of Comparative Example 4, the film was formed, but the bitter taste was significantly expressed and the physical properties of the film was not good. Comparative Example 1, Comparative Example 3, and Comparative Example 5, as expected from the test results when the sodium hydroxide was excluded from the formulation of Comparative Example 2, Comparative Example 4, Comparative Example 6, the bitter taste was expressed very badly and the active ingredient The physical properties of the film were very bad due to the increase of the dosage of.
  • Comparative Example 7 in Table 8 does not appear to mask the bitterness peculiar to sildenafil citrate as an experimental example of US652024.
  • Comparative Example 8 a bending test was performed 30 minutes after opening at a relative humidity of 55 RH at 22 ° C using Novartis Gas-X Thin Strips®, a commercially available high-content film for commercial use, and endured up to three times. I could see that.
  • Examples 1 to 4 2% of sodium hydroxide was added to the film weight without adding glycerin, and bending tests and sensory tests were performed using various plasticizers such as propylene glycol, polyethylene glycol 600, xylitol, and sorbitol. However, the bitter taste was excessively expressed and the bending test results did not improve.
  • the bitterness was well masked by the use of at least 4% by weight of sodium hydroxide (w / w), at least 1.4% by weight of magnesium oxide (w / w) and the use of a suitable high sweetener.
  • the exfoliation test result was not good due to the excessive increase of sodium hydroxide. Britness was also bad.
  • Example 15 Using a gas-X thin strip, the bending test was performed 30 minutes after opening at a relative humidity of 55% RH and 22 ° C. As a result of conducting the bending test under the same conditions, it was found that the results were surprising to withstand three times in Example 10 and seven times in Examples 11 to 14. In the case of Example 15, the bending test result was better, but it was found that it was difficult to apply because the peeling with the support PET film was not smooth in the cutting process for packaging.
  • the pharmaceutical composition of the present invention can be composed of oral film preparations containing various active ingredients as well as sildenafil or its pharmaceutically acceptable salts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/KR2013/001679 2012-02-28 2013-02-28 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름 WO2013129889A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2864322A CA2864322C (en) 2012-02-28 2013-02-28 High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
JP2014554675A JP5941558B2 (ja) 2012-02-28 2013-02-28 シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
IN1706MUN2014 IN2014MN01706A (OSRAM) 2012-02-28 2013-02-28
CN201380010759.1A CN104168895B (zh) 2012-02-28 2013-02-28 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
US14/379,989 US10092651B2 (en) 2012-02-28 2013-02-28 High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
EP13755861.5A EP2821066B1 (en) 2012-02-28 2013-02-28 High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2012-0020316 2012-02-28
KR1020120020316A KR101328350B1 (ko) 2012-02-28 2012-02-28 실데나필 또는 이의 약제학적으로 허용되는 염을 유효성분으로 함유하는 고미가 은폐된 약제학적 조성물
KR10-2012-0117233 2012-10-22
KR1020120117233A KR101440808B1 (ko) 2012-10-22 2012-10-22 실데나필 또는 이의 약제학적으로 허용되는 염을 고함량으로 포함하는 속용필름

Publications (3)

Publication Number Publication Date
WO2013129889A2 true WO2013129889A2 (ko) 2013-09-06
WO2013129889A3 WO2013129889A3 (ko) 2013-10-24
WO2013129889A9 WO2013129889A9 (ko) 2014-10-16

Family

ID=49083410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/001679 WO2013129889A2 (ko) 2012-02-28 2013-02-28 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름

Country Status (7)

Country Link
US (1) US10092651B2 (OSRAM)
EP (1) EP2821066B1 (OSRAM)
JP (1) JP5941558B2 (OSRAM)
CN (1) CN104168895B (OSRAM)
CA (1) CA2864322C (OSRAM)
IN (1) IN2014MN01706A (OSRAM)
WO (1) WO2013129889A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103989661A (zh) * 2014-05-26 2014-08-20 苏州大学 西地那非口腔速溶膜剂及其制备方法
JP2017526751A (ja) * 2014-09-02 2017-09-14 ソウル ファーマ カンパニー リミテッド タダラフィル口腔崩解フィルム及びこの製造方法
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537127A (ja) * 2014-12-09 2017-12-14 モノソル アールエックス リミテッド ライアビリティ カンパニー 線状多糖をベースとするフィルム製品
CN104586820B (zh) * 2015-01-13 2021-04-09 齐鲁制药有限公司 具有高载药量的西地那非口腔速溶薄膜组合物
CN104546807B (zh) * 2015-01-21 2020-09-01 齐鲁制药有限公司 奥氮平口腔速溶膜剂
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
WO2017214187A1 (en) * 2016-06-07 2017-12-14 Aridis Pharmaceuticals, Inc. Method for preparation of quick dissolving thin films containing bioactive material with enhanced thermal stability
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
US11096892B2 (en) * 2017-03-13 2021-08-24 Nano And Advanced Materials Institute Limited High loading and fast disintegration film for fast drug absorption
CN106860404A (zh) * 2017-04-13 2017-06-20 中国药科大学 一种枸橼酸西地那非掩味树脂复合物及其应用
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
CN109717282A (zh) * 2017-10-30 2019-05-07 上海冠生园食品有限公司 一种富含花青素的糖果及其制备方法
US20210007977A1 (en) * 2018-02-19 2021-01-14 Monell Chemical Senses Center Compositions and methods of ameliorating pharmaceutical aversiveness with salts
CN109010324B (zh) * 2018-08-30 2021-07-02 南京康川济医药科技有限公司 一种西地那非口溶膜剂及其制备方法
CN111466564A (zh) * 2019-01-24 2020-07-31 甄崇礼 含有天然活性多糖的口腔速溶膜剂及其制备方法
CN110128429A (zh) * 2019-04-30 2019-08-16 孙常全 一种西地那非-安赛蜜盐型及其制备方法和用途
KR20220061952A (ko) * 2019-09-04 2022-05-13 시즌스 바이오테크놀로지 (타이저우) 컴퍼니 리미티드 구강 미각 차폐용 보티옥세틴 하이드로브로마이드 함유 코팅 과립, 고체분산체 및 제제
GR20200100430A (el) * 2020-06-01 2022-01-13 Κυριακος Ηλια Κυπραιος Ταχεως διαλυομενες στοματικες ταινιες για τη χορηγηση δια της στοματικης οδου φαρμακων και λοιπων βιοδραστικων ουσιων σε ανθρωπους
EP4266902A4 (en) * 2020-12-22 2024-11-20 Solugen, Inc. BITTER MASKING AGENT
CN115252587A (zh) * 2022-08-19 2022-11-01 南京泛太化工医药研究所 一种口腔速溶膜及其制备方法
CN116270553B (zh) * 2023-02-01 2024-05-07 北京悦康科创医药科技股份有限公司 一种爱地那非口溶膜剂及其制备方法

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652024A (en) 1898-12-08 1900-06-19 James Gray Valve mechanism for automatic water-heaters.
KR100262926B1 (ko) 1993-06-09 2000-09-01 디. 제이. 우드, 무어 제임스 더블유 임포텐스 치료용 피라졸로피리미디논
WO2001070194A1 (en) 2000-03-23 2001-09-27 Warner-Lambert Company Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
KR100354310B1 (ko) 1994-04-29 2002-12-26 화이자 인코포레이티드 아지스로마이신투여방법
KR100357411B1 (ko) 1994-01-21 2003-02-05 아이코스 코포레이션 테트라시클릭유도체,제조방법및용도
WO2003070227A1 (de) 2002-02-21 2003-08-28 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte film- oder oblatenförmige arzneizubereitung
KR100430355B1 (ko) 1997-11-12 2004-05-04 바이엘 악티엔게젤샤프트 포스포디에스테라제 저해제로서의 2-페닐 치환된이미다조트리아지논
KR20060031552A (ko) 2004-10-08 2006-04-12 박영국 취수선을 이용한 해양 심층수 취수 방법
KR100627199B1 (ko) 1999-01-21 2006-09-22 라비팜 라보라토리즈, 인크. 점막 전달용 조성물 및 방법
US20070292515A1 (en) 2006-03-16 2007-12-20 Schobel Alexander M Solid dosage form containing a taste masked active agent
US20080220029A1 (en) 2007-03-05 2008-09-11 Charlene Ng Fast-dissolving/disintegrating film preparation having high proportion of active
US20080233174A1 (en) 2007-01-12 2008-09-25 Monosol Rx, Llc High dose film compositions and methods of preparation
US20090047330A1 (en) 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
KR101074271B1 (ko) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
KR20120101301A (ko) 2011-02-11 2012-09-13 주식회사 씨티씨바이오 실데나필 유리염기 함유 필름 제제 및 이의 제조 방법
KR101188594B1 (ko) 2011-12-06 2012-10-08 (주)씨엘팜 쓴맛이 차단된 실데나필 시트르산의 구강내 속붕해 필름제형

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW271400B (OSRAM) * 1992-07-30 1996-03-01 Pfizer
WO2002005820A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
WO2007059591A1 (en) * 2005-11-28 2007-05-31 Imaginot Pty Ltd Oral therapeutic compound delivery system
KR101304343B1 (ko) 2006-04-06 2013-09-11 한미사이언스 주식회사 Ｐｄｅ-5 억제제의 경구용 속용제형
EP2444072A3 (en) 2006-10-02 2014-05-07 Labtec GmbH Non-mucoadhesive film dosage forms
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
DE102010049708A1 (de) * 2010-10-28 2012-05-03 Hexal Ag Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652024A (en) 1898-12-08 1900-06-19 James Gray Valve mechanism for automatic water-heaters.
KR100262926B1 (ko) 1993-06-09 2000-09-01 디. 제이. 우드, 무어 제임스 더블유 임포텐스 치료용 피라졸로피리미디논
KR100357411B1 (ko) 1994-01-21 2003-02-05 아이코스 코포레이션 테트라시클릭유도체,제조방법및용도
KR100354310B1 (ko) 1994-04-29 2002-12-26 화이자 인코포레이티드 아지스로마이신투여방법
KR100430355B1 (ko) 1997-11-12 2004-05-04 바이엘 악티엔게젤샤프트 포스포디에스테라제 저해제로서의 2-페닐 치환된이미다조트리아지논
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
KR100627199B1 (ko) 1999-01-21 2006-09-22 라비팜 라보라토리즈, 인크. 점막 전달용 조성물 및 방법
WO2001070194A1 (en) 2000-03-23 2001-09-27 Warner-Lambert Company Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent
WO2003070227A1 (de) 2002-02-21 2003-08-28 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte film- oder oblatenförmige arzneizubereitung
KR20060031552A (ko) 2004-10-08 2006-04-12 박영국 취수선을 이용한 해양 심층수 취수 방법
US20070292515A1 (en) 2006-03-16 2007-12-20 Schobel Alexander M Solid dosage form containing a taste masked active agent
US20080233174A1 (en) 2007-01-12 2008-09-25 Monosol Rx, Llc High dose film compositions and methods of preparation
US20080220029A1 (en) 2007-03-05 2008-09-11 Charlene Ng Fast-dissolving/disintegrating film preparation having high proportion of active
US20090047330A1 (en) 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
KR101074271B1 (ko) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
KR20120101301A (ko) 2011-02-11 2012-09-13 주식회사 씨티씨바이오 실데나필 유리염기 함유 필름 제제 및 이의 제조 방법
KR101188594B1 (ko) 2011-12-06 2012-10-08 (주)씨엘팜 쓴맛이 차단된 실데나필 시트르산의 구강내 속붕해 필름제형

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2821066A4

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103989661A (zh) * 2014-05-26 2014-08-20 苏州大学 西地那非口腔速溶膜剂及其制备方法
JP2017526751A (ja) * 2014-09-02 2017-09-14 ソウル ファーマ カンパニー リミテッド タダラフィル口腔崩解フィルム及びこの製造方法
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate

Also Published As

Publication number Publication date
IN2014MN01706A (OSRAM) 2015-05-29
US20150025084A1 (en) 2015-01-22
CN104168895B (zh) 2020-02-21
CA2864322C (en) 2016-08-09
EP2821066A2 (en) 2015-01-07
JP2015504916A (ja) 2015-02-16
WO2013129889A3 (ko) 2013-10-24
EP2821066A4 (en) 2015-10-21
EP2821066B1 (en) 2018-04-25
WO2013129889A9 (ko) 2014-10-16
US10092651B2 (en) 2018-10-09
JP5941558B2 (ja) 2016-06-29
CN104168895A (zh) 2014-11-26
CA2864322A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
WO2013129889A2 (ko) 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
WO2010151020A2 (ko) 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
EP2054031B1 (en) Transmucosal delivery devices with enhanced uptake
US9101625B2 (en) Buprenorphine-wafer for drug substitution therapy
WO2010150930A1 (ko) 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
WO2012121461A1 (ko) 안정한 경구용 속용 필름 제제
CN110337290A (zh) 舌下右旋美托咪啶用于治疗激越的用途
KR101553207B1 (ko) 도네페질 또는 그의 약제학적으로 허용되는 염을 함유한 구강붕해필름 제제 및 그의 제조방법
KR20090020561A (ko) 필름 피복된 고체 투여 형태
US20250009729A1 (en) Donepezil oral films
KR101328350B1 (ko) 실데나필 또는 이의 약제학적으로 허용되는 염을 유효성분으로 함유하는 고미가 은폐된 약제학적 조성물
KR20180125664A (ko) 솔리페나신을 유효성분으로 하는 구강붕해필름
KR102153894B1 (ko) 온단세트론 또는 이의 염을 함유하는 구강 붕해형 필름 제제 및 이의 제조방법
KR101440808B1 (ko) 실데나필 또는 이의 약제학적으로 허용되는 염을 고함량으로 포함하는 속용필름
WO2014104840A1 (ko) 신규한 마이크로그래뉼 제형
AU2011224107B2 (en) Buprenophine-wafer for drug substitution therapy
WO2016052781A1 (ko) 엔테카비르 함유 구강 붕해 필름제형
HK40082930B (en) Transmucosal therapeutic system containing agomelatine
HK40082930A (en) Transmucosal therapeutic system containing agomelatine
HK40082929B (en) Transmucosal therapeutic system containing agomelatine
HK40082929A (en) Transmucosal therapeutic system containing agomelatine
HK40014031A (en) Use of sublingual dexmedetomidine for the treatment of agitation
HK1131344B (en) Transmucosal delivery devices with enhanced uptake

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13755861

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014554675

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2864322

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14379989

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2013755861

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013755861

Country of ref document: EP